MYGN MYRIAD GENETICS INC Insider Trading

Director Bisaro Paul buys 7,500 shares of MYGN at $3.685 on 2026-05-14; stock down 26.3% in 30 days.

Bisaro Paul, a director, purchased 7,500 shares at $3.685, bringing his post-transaction holdings to 97,441 shares. The purchase occurred as the stock traded at $3.62 on the filing date, down 26.3% over the prior 30 days and 19.4% over 90 days from a 52-week high of $8.59. MYRIAD GENETICS remains unprofitable with net income of $-34.1M in the latest quarter despite quarterly revenue of $200.4M, and the company faces headwinds including annual revenue decline of -1.6%. The timing of this insider buy coincides with significant recent price weakness, though the available data does not indicate the director's specific motivations or investment thesis.

CEO Raha Samraat S. buys 40,000 shares of MYGN at $5.00; holds 493.1K shares (+8.8%) as stock down -54.3% from 52-week high.

Raha Samraat S., President and CEO, purchased 40,000 shares at $5.00 on 2026-03-09, increasing his holdings from 453.1K to 493.1K shares. This transaction occurred while MYRIAD GENETICS trades -54.3% below its 52-week high of $10.52 and the company faces material headwinds: net income of $-27.4M on quarterly revenue of $205.7M, annual revenue contraction of -1.6%, and unprofitability over the most recent full fiscal year. The purchase itself is discrete, but it arrives against a backdrop of sustained stock deterioration (-34.6% over 90 days, -6.0% over 30 days) and operational distress. The absolute price level ($5.00) and the magnitude of acquisition (8.8% increase to CEO holdings) merit investor attention to understand management's confidence thesis in a period of both market decline and negative earnings.

Director Phanstiel S. Louise bought 104,507 shares over 3 days at average $4.73; holdings rose 58.9% to 281,951 shares

Phanstiel S. Louise executed 3 separate purchases totaling 104,507 shares for $494,722.42 between 2026-02-25 and 2026-02-27 at an average blended price of $4.73, increasing her holdings by 58.9% to 281,951 shares. The transaction occurred in a context of significant stock price weakness: MYGN trades at $4.61 currently, down 66.6% from its 52-week high of $13.78 and down 39.6% over the past 90 days. The company reported a net loss of $27,400,000 for its latest quarter and is unprofitable on a full-year basis, with flat annual revenue growth of -1.6%. The director's prior open-market purchase across all tickers returned +60.6% over 30 days on average, though this cross-ticker track record does not constitute predictive evidence specific to MYGN.

Director Reitan sold 46,012 shares of MYGN at $27.95 on 2024-09-03 via 10b5-1 plan; holdings reduced to 42,533 shares post-sale.

Reitan Colleen F, a Director, sold 46,012 shares at $27.95 under a pre-arranged 10b5-1 trading plan on 2024-09-03, reducing her holdings from 88,545 shares to 42,533 shares—a 52.0% reduction in her position. Because this transaction is part of a scheduled 10b5-1 plan, it reflects a pre-determined execution rather than a discretionary market decision. The sale totaled $1,285,851.35. Investors should review the timing and pricing history of the 10b5-1 plan's adoption and any concurrent director activity to assess whether this reduction signals a broader capital allocation shift or confidence change.